There is currently limited clinical (human) data available on the safety profile of Panax notoginseng.
Cases of skin rash have been observed following intravenous administration of Panax notoginseng.[1] Furthermore, other studies have reported cases of nausea, vomiting, and dry mouth.[2]
Additionally, Panax notoginseng is a CYP1A2 inducer, which means that it may interact with medications or other substances metabolized by this enzyme class.[3]